-
Mashup Score: 0
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
Source: Oncology CentralCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
#JEMPERLO #Dostarlimab has been approved by the #FDA for use in dMMR recurrent or advanced #EndometrialCancer. Read the latest news on @OncologyCentral now: https://t.co/hZ0mHyjoVx